AMENDMENTS TO THE CLAIMS

1. (Currently amended) A tripeptide or an alkyl ester thereof selected from the group consisting of substituted or unsubstituted Phe-Phe-Pro, Pro-Phe-Phe, Phe-Phe-Ser, Ser-Phe-Phe, Phe-Phe-Asn and Asn-Phe-Phe said tripeptide comprising a not terminal proteolytic enzyme cleavable amino acid moiety that is connected to ~~as~~ a drug said drug being a drug for the treatment of arthritis, invasive parasitic diseases, Paludism (Malaria), AIDS, tumors and cancer ~~or pharmacologically active site or pharmacologically active group with the proviso that it is not prolyl-m-sarcolysyl-p-fluoro-phenylalanine~~.

2. (Previously presented) The tripeptide of claim 1, which is an alkyl ester with the alkyl group being a methyl or an ethyl group, preferably an ethyl group.

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Previously presented) The tripeptide of claim 1, wherein the terminal Phe is fluoro substituted in para position.

7. (Currently amended) ~~The~~ A tripeptide ~~of claim 1~~ wherein the proteolytic enzyme cleavable amino acid moiety is substituted with a substituent sufficiently reactive to be useful in drug coupling reactions, with the proviso that said substituent is not --$N(CH_2$—CH_2--$Cl)_2$ in meta position on the not terminal Phe of Pro-Phe-p-F-Phe.

8. (Previously presented) The tripeptide of claim 7 wherein the proteolytic enzyme cleavable amino acid moiety is or comprises Phe.

9. (Canceled)

10. (Canceled)

11. (Previously presented) The tripeptide of claim 10 wherein the drug is adriamycin.

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Previously presented) A pharmaceutical composition comprising a tripeptide of claim 1.

17. (Canceled)

18. (Previously presented) The tripeptide of claim 1 that is a substituted or unsubstituted Pro-Phe-Phe.

19. (Canceled)

20. (Previously presented) The tripeptide of claim 6 wherein the peptide is Pro-Phe-p-F-Phe.